DDInter458 DDInter1577
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name Orgovyx, for the treatment of advanced prostate cancer.[L27991,L27996] This branded product was later approved by the European Commission on April 29, 2022. Relugolix has also been studied in the symptomatic treatment of endometriosis. Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer - similar therapies such as [degarelix] require subcutaneous administration - and therefore provides a less burdensome therapeutic option for patients who might otherwise require clinic visits for administration by healthcare professionals. In addition to its relative ease-of-use, relugolix was shown to be superior in the depression of testosterone levels when compared to [leuprolide], another androgen deprivation therapy used in the treatment of prostate cancer. In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and [norethindrone] under the market name Myfembree for the first once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Cyclosporine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Enzalutamide
Enzalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Relugolix
Cyclosporine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Formoterol
Formoterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Relugolix
Cyclosporine {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Enzalutamide
Enzalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Relugolix
Cyclosporine {u} (Compound) causes {v} (Side Effect) Injury
Injury {u} (Side Effect) is caused by {v} (Compound) Formoterol
Formoterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Relugolix
Cyclosporine {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Lapatinib
Lapatinib {u} may lead to a major life threatening interaction when taken with {v} Relugolix
Cyclosporine {u} (Compound) causes {v} (Side Effect) Injury
Injury {u} (Side Effect) is caused by {v} (Compound) Clarithromycin
Clarithromycin {u} may lead to a major life threatening interaction when taken with {v} Relugolix
Cyclosporine {u} (Compound) upregulates {v} (Gene) PSAT1
PSAT1 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Relugolix
Cyclosporine {u} (Compound) upregulates {v} (Gene) PSAT1
PSAT1 {u} (Gene) is upregulated by {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Relugolix
Cyclosporine {u} (Compound) upregulates {v} (Gene) PSAT1
PSAT1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Vemurafenib {u} may lead to a major life threatening interaction when taken with {v} Relugolix
Cyclosporine {u} (Compound) upregulates {v} (Gene) DDIT3
DDIT3 {u} (Gene) is downregulated by {v} (Compound) Dexamethasone
Dexamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Relugolix
Cyclosporine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound) and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Cyclosporine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Formoterol (Compound) and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Cyclosporine (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound) and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Cyclosporine (Compound) causes Injury (Side Effect) and Injury (Side Effect) is caused by Formoterol (Compound) and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Cyclosporine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Lapatinib (Compound) and Lapatinib may lead to a major life threatening interaction when taken with Relugolix
Cyclosporine (Compound) causes Injury (Side Effect) and Injury (Side Effect) is caused by Clarithromycin (Compound) and Clarithromycin may lead to a major life threatening interaction when taken with Relugolix
Cyclosporine (Compound) upregulates PSAT1 (Gene) and PSAT1 (Gene) is upregulated by Dabrafenib (Compound) and Dabrafenib may cause a minor interaction that can limit clinical effects when taken with Relugolix
Cyclosporine (Compound) upregulates PSAT1 (Gene) and PSAT1 (Gene) is upregulated by Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Cyclosporine (Compound) upregulates PSAT1 (Gene) and PSAT1 (Gene) is upregulated by Vemurafenib (Compound) and Vemurafenib may lead to a major life threatening interaction when taken with Relugolix
Cyclosporine (Compound) upregulates DDIT3 (Gene) and DDIT3 (Gene) is downregulated by Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Relugolix